Manic switch and serotonin syndrome induced by augmentation of paroxetine with methylphenidate in a patient with major depression

  title={Manic switch and serotonin syndrome induced by augmentation of paroxetine with methylphenidate in a patient with major depression},
  author={Young-Min Park and Yeon Kyung Jung},
  journal={Progress in Neuro-Psychopharmacology and Biological Psychiatry},
  • Young-Min ParkY. Jung
  • Published 30 May 2010
  • Psychology
  • Progress in Neuro-Psychopharmacology and Biological Psychiatry

Serotonin Syndrome in Children and Adolescents Exposed to Selective Serotonin Reuptake Inhibitors - A Review of Literature.

  • Siqi XuevA. Ickowicz
  • Medicine, Psychology
    Journal of the Canadian Academy of Child and Adolescent Psychiatry = Journal de l'Academie canadienne de psychiatrie de l'enfant et de l'adolescent
  • 2021
Serotonin syndrome is a severe adverse drug reaction associated with SSRI, and can be associated with diverse presentations in the pediatrics population and diagnostic challenges, and Clinicians are recommended to be vigilant in the monitoring and recognition of serotonin syndrome.

Management of severe arterial hypertension associated with serotonin syndrome: a case report analysis based on systematic review techniques

It is concluded that classic antihypertensives may not be effective for the treatment of severe hypertension associated with serotonin syndrome, and patients with severe hypertension not responding to benzodiazepines may benefit from cyproheptadine, propofol or both.

Pharmacological means to improve patients’ mood. Are they effective and safe?

Simple and proven drugs that improve patients mood and, some of them do have proven antidepressant activity are discussed, methylphenidate, ketamine, cannabinoids and buprenorphine.

Polypharmacy with antidepressants in children and adolescents.

Preliminary evidence points to the potential clinical usefulness of some polypharmacy patterns, although there is still little efficacy and safety information, and further research on patients with co-morbidities or more severe conditions is needed.



Frequency of stimulant treatment and of stimulant-associated mania/hypomania in bipolar disorder patients.

This is the largest study on amphetamine/ methylphenidate treatment and associated mania/hypomania in BD patients and finds absence of axis-I comorbidity was associated with stimulant-associated mania.

Combined treatment with methylphenidate and citalopram for accelerated response in the elderly: an open trial.

Methylphenidate augmentation of citalopram may be a safe and viable strategy for accelerating antidepressant response in elderly depressed patients and needs to be confirmed in a placebo-controlled trial.

The serotonin syndrome.

The serotonin syndrome is a potentially life-threatening drug reaction that may result from therapeutic medication use, self-poisoning, or interactions between drugs.

Serotonin syndrome induced by augmentation of SSRI with methylphenidate

The first reported case of serotonin syndrome induced by augmentation of SSRI with methylphenidate is presented, and it is believed that the present patient’s episode satisfied criteria for serotonin syndrome.

Venlafaxine‐associated serotonin syndrome and manic episode in a geriatric depressive patient

A geriatric depressive patient, who developed both serotonin syndrome and manic episode rapidly after having received two doses of 37.5 mg venlafaxine on the top of her existing medications, is reported to alert psychiatrists about producing accumulative serotonergic effects from combined use of psychoactive drugs.

Effects of Methylphenidate on Extracellular Dopamine, Serotonin, and Norepinephrine: Comparison with Amphetamine

The hypothesis that a stimulant‐induced increase in serotonin is necessary for the appearance of stereotyped behaviors is not supported, as methylphenidate promotes a dose‐dependent behavioral profile that is very comparable to that of amphetamine.